ArticleJACC. Case reports2026
Percutaneous Debulking of Bioprosthetic Mitral Valve Vegetations: Preserving Valve Function in Recurrent Infective Endocarditis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Percutaneous Mechanical Aspiration of Left-Sided Intracardiac Masses for Prohibitive Surgical Candidates: A Single-Center Experience.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Percutaneous Vacuum-Assisted Debulking of Infected and Non-Infected Left-Sided Cardiac Masses Using the AngioVac System: A Systematic Review of Published Case Reports and Case Series.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfective endocarditis involving a prosthetic mitral valve carries high morbidity, especially when complicated by embolic events. Repeat surgery is often not feasible in high-risk patients. CASE SUMMARY: An 81-year-old man with a mitral valve bioprosthesis presented with recurrent infective endocarditis due to Streptococcus mutans, with enlarging vegetations and embolic strokes. Given prohibitive surgical risk, he underwent successful percutaneous debulking using the AngioVac system via transseptal approach under transesophageal echocardiographic and fluoroscopic guidance. Long-term suppressive antibiotics were continued. At the 30-month follow-up, the valve was structurally intact with no evidence of recurrent endocarditis. DISCUSSION: This case highlights the utility of AngioVac debulking of left-sided prosthetic valve vegetations in nonsurgical candidates. Successful imaging-guided aspiration minimized embolic risk and preserved valve function. TAKE-HOME MESSAGE: Vacuum-assisted debulking with AngioVac via a transseptal approach is a viable option in high-risk patients with prosthetic mitral valve endocarditis, offering an alternative to reoperation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.